Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|23|2370-2385

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.23, 2011-08, pp. : 2370-2385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hiroshi Maeda - defining the pathway to targeted cancer therapy

By Duncan Ruth   Seymour Len  

Journal of Drug Targeting, Vol. 15, Iss. 7-8, 2007-08 ,pp. : 456-456

Informa Healthcare

Access to resources Recommend Favorite

Repairing collateral damage in MS

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Tolerance Induction During Therapy with Long-Acting Nitrates: How Extensive is the “Collateral Damage”?

By Horowitz John  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 1, 2004-01 ,pp. : 11-12

Springer Publishing Company

Access to resources Recommend Favorite

Is addiction's collateral damage culturally invariant?

By Humphreys Keith  

Addiction Research and Theory, Vol. 14, Iss. 6, 2006-12 ,pp. : 647-648

Informa Healthcare

Access to resources Recommend Favorite

Potential Gene Therapy Strategies for Cancer Stem Cells

By  

Current Gene Therapy, Vol. 6, Iss. 5, 2006-10 ,pp. : 579-591

Bentham Science Publishers

Access to resources Recommend Favorite